UNSPSC 51182033: Metenolone

This classification denotes an anabolic agent with the molecular formula C20H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9062ZT8Q5C, chemically known as androst-1-en-3-one, 17-hydroxy-1-methyl-, (5alpha,17beta)- but generally known as metenolone, which bears US NIH Compound Identifier 9054. European Medicines Agency schedules Metenolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08823MIG.

World Health Organization schedules metenolone in its Anatomical Therapeutic Chemical (ATC) Classification. METENOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metenolone under HS 29372900 and SITC 54153. SMILES: OC1C2(C(C3C(C4(C(CC3)CC(=O)C=C4C)C)CC2)CC1)C.

UNSPSC 51182033 Metenolone is a Commodity code capturing pharmaceutical active ingredients and finished-dose preparations that state and local healthcare systems purchase through cooperative purchasing vehicles and multi-source procurement agreements. Recent activity shows state and local buyers procuring generic pharmaceuticals and over-the-counter products—including metenolone and related anabolic agents—through established wholesaler networks under multi-year contracts with volume-based pricing. The issuing bodies are primarily state healthcare purchasing coalitions administering cooperative procurement on behalf of multiple participating jurisdictions, including state agencies, local health departments, and other government facilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with proposals due March 26, 2026. The RFP requires vendors to distribute through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), maintain cGMP and Drug Supply Chain Security Act compliance, hold minimum insurance coverage including $5 million commercial general liability per occurrence, and demonstrate pricing flexibility across flat price, net price, and WAC-minus formats. Evaluation weighs price competitiveness at 75 percent, with the remaining 25 percent distributed across administrative fee format compliance, EDI capability, fixed pricing, and willingness to accept a 3 percent administrative fee. The procurement spans Minnesota and Oregon, with awarded vendors subject to performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials.